Informations:
Erreur:
ID
33700
Description
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT02121483
Lien
https://clinicaltrials.gov/show/NCT02121483
Mots-clés
Versions (1)
- 20/12/2018 20/12/2018 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
20 décembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Diabetes Mellitus, Type 2 NCT02121483
Eligibility Diabetes Mellitus, Type 2 NCT02121483
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT02121483
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Children | Adolescents | Diabetes Mellitus, Non-Insulin-Dependent
Item
children and adolescents with type 2 diabetes mellitus
boolean
C0008059 (UMLS CUI [1])
C0205653 (UMLS CUI [2])
C0011860 (UMLS CUI [3])
C0205653 (UMLS CUI [2])
C0011860 (UMLS CUI [3])
Poor glycemic control | Hemoglobin A1c measurement | Diet therapy | Exercise | Metformin Stable | Insulin Basal Stable
Item
insufficient glycaemic control (hba1c =10.5%) despite diet and exercise and/or stable metformin and/or stable basal insulin
boolean
C0342299 (UMLS CUI [1])
C0474680 (UMLS CUI [2])
C0012159 (UMLS CUI [3])
C0015259 (UMLS CUI [4])
C0025598 (UMLS CUI [5,1])
C0205360 (UMLS CUI [5,2])
C0021641 (UMLS CUI [6,1])
C0205112 (UMLS CUI [6,2])
C0205360 (UMLS CUI [6,3])
C0474680 (UMLS CUI [2])
C0012159 (UMLS CUI [3])
C0015259 (UMLS CUI [4])
C0025598 (UMLS CUI [5,1])
C0205360 (UMLS CUI [5,2])
C0021641 (UMLS CUI [6,1])
C0205112 (UMLS CUI [6,2])
C0205360 (UMLS CUI [6,3])
Islet Cell Antigen Negative | Glutamic Acid Decarboxylase Antibody Negative | Fasting C-peptide level
Item
negative for islet cell antigen and glutamic acid decarboxylase autoantibodies and fasting c-peptide levels >= 0.85 ng/ml
boolean
C1522529 (UMLS CUI [1,1])
C0003320 (UMLS CUI [1,2])
C1513916 (UMLS CUI [1,3])
C0443891 (UMLS CUI [2,1])
C1513916 (UMLS CUI [2,2])
C2208720 (UMLS CUI [3])
C0003320 (UMLS CUI [1,2])
C1513916 (UMLS CUI [1,3])
C0443891 (UMLS CUI [2,1])
C1513916 (UMLS CUI [2,2])
C2208720 (UMLS CUI [3])
Body mass index | Age | Gender
Item
bmi > 50th percentile for age and sex
boolean
C1305855 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
C0001779 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Hyperglycemia Uncontrolled | Glucose measurement
Item
uncontrolled hyperglycaemia with a glucose level > 240 mg/dl (> 13.3 mmol/l)
boolean
C0020456 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0337438 (UMLS CUI [2])
C0205318 (UMLS CUI [1,2])
C0337438 (UMLS CUI [2])
Acute metabolic decompensation | Diabetic Ketoacidosis
Item
history of acute metabolic decompensation such as diabetic ketoacidosis within 3 months before the screening visit with the exception of acute de-compensation at the time of type 2 diabetes diagnosis
boolean
C2673978 (UMLS CUI [1])
C0011880 (UMLS CUI [2])
C0011880 (UMLS CUI [2])
Insulin, Short-Acting
Item
current short-acting insulin or having received short-acting insulin for more than 3 days within 12 weeks prior to randomisation
boolean
C0356365 (UMLS CUI [1])
Weight-Loss Agents
Item
treatment with weight reduction medications within 4 weeks before randomisation
boolean
C0376606 (UMLS CUI [1])